Home > Press > AMAG Pharmaceuticals, Inc. to Present at Two Upcoming Healthcare Conferences
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that Brian J.G. Pereira, MD, President and CEO of AMAG Pharmaceuticals, Inc. will present an overview of the Company at the Bear Stearns 20th Annual Healthcare Conference at 9:00 a.m. ET on Tuesday, September 11, 2007. The conference is being held at the Grand Hyatt Hotel in New York.
AMAG Pharmaceuticals, Inc. to Present at Two Upcoming Healthcare Conferences
CAMBRIDGE, MA | Posted on September 5th, 2007
Dr. Pereira will also present a corporate overview at the UBS Global Life Sciences Conference at 1:30 p.m. ET on Wednesday, September 26, 2007. This conference is also being held at the Grand Hyatt Hotel in New York.
Live audio webcasts of these presentations will be accessible through the Investors section of the company's web site at http://www.amagpharma.com . Following the conferences, the audio webcasts will be archived on the AMAG Pharmaceuticals, Inc. web site until October 27, 2007.
About AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia, as well as novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease.
Ferumoxytol, the Company’s lead product candidate, is being developed for use as an intravenous iron replacement therapeutic for the treatment of iron deficiency anemia in chronic kidney disease patients. The Company has released data on all four planned Phase III clinical trials of ferumoxytol as an intravenous iron replacement therapeutic in chronic kidney disease patients.
Combidex®, the Company’s other product under development, is an investigational functional molecular imaging agent consisting of iron oxide nanoparticles for use in conjunction with MRI to aid in the differentiation of cancerous from normal lymph nodes. In March 2005, the Company received an approvable letter from the FDA with respect to Combidex, subject to certain conditions.
For more information, please click here
AMAG Pharmaceuticals, Inc.
Copyright © Business Wire 2007
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
European Technology Platform for Nanomedicine and Nanomed2020 European Consortium Launch the Nanomedicine Award June 17th, 2013
Dr. Ben J. Lipps designated as Chairman of the Management Board and Chief Executive Officer of Nanostart-holding MagForce AG June 17th, 2013
Iranian Scientists Produce Dynamometer for Nanoparticles, Biocells June 15th, 2013
Discovery of new material state counterintuitive to laws of physics June 14th, 2013
An Innovative material for the Green Earth: Simple and inexpensive process to make a material for CO2 adsorption June 17th, 2013
Polymer-coated catalyst protects "artificial leaf" June 17th, 2013
Efficient and inexpensive: Researchers develop catalyst material for fuel cells: Platinum-nickel nano-octahedra save 90 percent platinum June 17th, 2013
AXEON Acquires Assets of Leading Reverse Osmosis Systems Manufacturer June 17th, 2013
Discover the ‘Nanostructure Advantage’ at ECerS 2013, Booth 5: Innovnano presents nanostructured powders for high performance ceramics June 17th, 2013
SEMATECH to Address Critical Supply Chain Challenges and Present Latest Technology Advances at SEMICON West 2013 June 17th, 2013
Imec shows multiple enhancement options for next-generation FinFETs: Leading nano-electronics R&D center addresses key challenges of Germanium finFET technology at VLSI 2013 June 14th, 2013
Imec showcases innovation in RRAM R&D at VLSI Technology Symposium June 14th, 2013